Pfizer Q2 2026 Shows Non-COVID Portfolio Becomes Main Growth Engine
Pfizer’s Q2 2026 results show a shift toward its non-COVID portfolio. Revenues excluding Comirnaty and Paxlovid rose 5% operationally, while launched and acquired products grew 18%. The strategy relies on acquisitions such as Seagen, Metsera and Biohaven, with Padcev a notable contributor to growth.